Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients

NCT02267993 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Thrombocytopenia

Interventions

DRUG: recombinant human thrombopoietin

Sponsor

Institute of Hematology & Blood Diseases Hospital, China